The Morningside Companies' Proud Past

Origins in Exports

1991 to 2004

  • Founded in 1991
  • Focus on supply to private sector export markets in developing countries
  • Established a reputation for excellence and reliability of supply with NGOs and major UN aid agencies
  • First UK Marketing Authorisation (2005): Metformin Tablets
Morningside Pharmaceuticals Ltd has a rich history

Picture: The Morningside Team at their stand, during an International Exhibition. 

Growth in the UK & Export Markets

2005 to 2012

  • Established a sales & marketing, Quality Assurance and regulatory presence in the UK 
  • First third party contract supply order (2006)
  • Focus on niche, high-value molecules
  • 50+ Marketing Authorisations secured
  • Growing infrastructure with the addition of three distribution centres
  • Building an international and UK distribution network
Morningside Pharmaceuticals Ltd has a rich history

Picture: Morningside customers during an event in Guyana, South America.

Intellectual Property Led Growth

2012 to 2016

  • Morningside wins the Queen’s Award for Innovation: International Trade 2012
  • The Morningside companies establish a Research & Development capability. 
    • The first product launched with full IP ownership (Sodium Fluoride Toothpaste: 2015)
  • Completed substantial marketing investment to launch the Headline Brand range
  • Development of supply to NHS hospitals, driving high growth and consistent supply
  • Further investment in infrastructure and new GMP approved buildings

Picture: Morningside’s Distribution Centre, in Loughborough, United Kingdom.

Sector Leading Success

2016 to Today

  • Prime Minister Theresa May hails Morningside as ‘the best of British’ during a trade mission to India (2016)
  • Morningside wins the Innovation in Generics Award at the Pharmacy Business Awards (2017)
  • The Leicester Arena is renamed the Morningside Arena, as part of a major naming-rights deal (2018)
  • Focus on key therapeutic areas 
  • Over 200 generic and branded licensed medicines in the UK and EU
  • Significant opportunity to expand into new global markets